Routine assessment of male infertility through sperm analysis has vast implications on human reproductive health. According to an estimate, almost half of the causes of infertility comprise male-related one. Usually, the assessment—concentration, motility, and morphology–identifies the problem but not the cause of it. The lack of clinical effectiveness of such tests apart, couples only go for these after a year or so of unsuccessful attempt. This period stridently marks the period of uncertainty. A new international study aimed to change this.
The international team of researchers, notably including a biologist at Washington State University, have hit on the set of epigenetic biomarkers responsible for male infertility. Additionally, taking the research forward can potentially offer doctors expand the treatment options. The study looked at the genetic profile in both fertile and infertile men.
Period of Uncertainty in Diagnosing Male Infertility
The researchers attributed the nature of these biomarkers to groups of methyl molecules sperm DNA is associated with. For each type of biomarker they identified, they also suggested treatment options that could respond in treating the male infertility. They leveraged advanced epigenetic modifications technologies to arrive at their conclusion. The study is significant as it reduces the period of uncertainty in diagnosing the problem of male infertility. Also, it sheds light on potential treatment options. They are now striving to commercialize their diagnostic tools by going for a more elaborate clinical study in the near future.
Epigenetic Modifications Have Potential for Other Diseases As Well
The study, believe the health care fraternity, could help leverage the potential of epigenetic modifications for various other diseases. Particular case in points will be autism and arthritis. The advent of technologies used to analyze epigenetic biomarkers will help them in this pursuit.